Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.39 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28443283 | 1.00 | SLC22A6 (0.41) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL17921870 | 0.88 | SLC22A6 (0.45) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL4161257 | 0.83 | SLC22A6 (0.41) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL16138447 | 0.79 | ALOX15 (0.39) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL3183276 | 0.79 | GRIK1 (0.45) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL8520307 | 0.79 | GRIK1 (0.43) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL7407055 | 0.79 | GRIK1 (0.40) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL17636172 | 0.79 | GABRR1 (0.42) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL7407058 | 0.79 | GRIK1 (0.40) | SLC22A6GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL7733980 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088877-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-03-30 | — | — | US | disclosed |
| US-9540402-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160031911-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-02-04 | — | — | US | disclosed |
| EP-2455458-B1 | Covalent tethering of functional groups to proteins | PROMEGA CORP (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8921620-B2 | Compositions comprising a dehalogenase substrate and a contrast agent and methods of use | PROMEGA CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-8895787-B2 | Compositions comprising a dehalogenase substrate and a radionuclide and methods of use | PROMEGA CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| EP-1594962-B1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORP (US) | 2014-08-27 | — | — | EP | disclosed |
| US-RE42931-E1 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110033844-A1 | USE OF LYSOSOMAL CARBOXYPEPTIDASE C (PRCP) AS A THERAPEUTIC OR DIAGNOSTIC TARGET | BAYER HEALTHCARE AG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20100104501-A1 | PRSS23 AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-1998002578-A1 | SILANOL ENZYME INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-01-22 | — | — | WO | disclosed |
| US-5707848-A | DNA SEQUENCE CODE OF MUTANT SUBTILISIN PROTEIN MODIFIED TO LACK THE ABILITY TO BIND CALCIUM, EXPRESSION VECTORS AND TRANSFORMED HOST CELLS | UNIVERSITY OF MARYLAND (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1997046251-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0804592-A1 | CALCIUM FREE SUBTILISIN MUTANTS | UNIVERSITY OF MARYLAND (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996040197-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1997-04-24 | — | — | WO | disclosed |
| WO-1996040197-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5567601-A | GENETIC ENGINEERING | UNIVERSITY OF MARYLAND (US) | 1996-10-22 | — | — | US | disclosed |
| WO-1996009396-A1 | CALCIUM FREE SUBTILISIN MUTANTS | UNIVERSITY OF MARYLAND (US) | 1996-03-28 | — | — | WO | disclosed |
| US-5470733-A | Calcium free subtilisin mutants | UNIVERSITY OF MARYLAND (US) | 1995-11-28 | — | — | US | disclosed |
| US-5252558-A | Pentapeptide having specific inhibiting effect on epidermal cell proliferation, the salts thereof, pharmaceutical compositions comprising the same and a process for the preparation of the pentapeptide and the pharmaceutical compositions | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088877-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | GGT1, HDHD5, DNPH1 | SLC22A6 3769/4885GRIK1 4325/4885GRIK2 4405/4885 |
| US-20160031911-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | GGT1, HDHD5, DNPH1 | SLC22A6 3769/4885GRIK1 4325/4885GRIK2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.